Gregory J. Riely

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005)

William Pao, Vincent A. Miller, Katerina A. Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, ...

A specific secondary mutation in the kinase domain of the epidermal growth factor receptor can render cells insensitive to the two kinase inhibitors. This mutation was found in resistant tumors from...

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005)

William Pao, Vincent A. Miller, Katerina A. Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, ...

Background Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons...

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005)

William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, ...

Mutational analysis of the KRAS gene in lung cancer patients treated with two different kinase inhibitors suggests that tumors with KRAS mutations do not respond to these drugs.

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005)

William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, ...

Background Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors...

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, William, Wang, Theresa Y, Riely, Gregory J, Miller, Vincent A, Pan, Qiulu, Ladanyi, Marc, ...

Mutational analysis of the KRAS gene in lung cancer patients treated with two different kinase inhibitors suggests that tumors with KRAS mutations do not respond to these drugs

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, William, Miller, Vincent A, Politi, Katerina A, Riely, Gregory J, Somwar, Romel, Zakowski, Maureen F, ...

A specific secondary mutation in the kinase domain of the epidermal growth factor receptor can render cells insensitive to the two kinase inhibitors. This mutation was found in resistant tumors from...

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, William, Wang, Theresa Y, Riely, Gregory J, Miller, Vincent A, Pan, Qiulu, Ladanyi, Marc, ...

Mutational analysis of the KRAS gene in lung cancer patients treated with two different kinase inhibitors suggests that tumors with KRAS mutations do not respond to these drugs

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, William, Miller, Vincent A, Politi, Katerina A, Riely, Gregory J, Somwar, Romel, Zakowski, Maureen F, ...

A specific secondary mutation in the kinase domain of the epidermal growth factor receptor can render cells insensitive to the two kinase inhibitors. This mutation was found in resistant tumors from...